Unknown toxicity mechanisms and their effects hamper new drug discovery, causing huge research investment losses. Metabolon’s technology is uniquely positioned to accelerate MOA, identify biomarkers, further personalized medicine and tailor therapy approaches.

For the past 60 years, scientists have studied ethylene glycol monomethyl ether (EGME), a widely used industrial toxic compound that affects rapidly dividing cells. While over 200 papers on EGME toxicity exist, researchers have been unable to determine a specific mechanism of action.